Wharton's Jelly and Exosome Supplier for Rochester, NY Medspas

Physician-supervision requirements for medspa accounts

Precision Biologics sells only to licensed clinics, physicians, and medspas operating under physician supervision, not directly to patients and not to unsupervised aesthetic businesses. For a Rochester medspa, account setup includes confirming that a supervising physician is attached to the practice's NPI record before documentation or pricing is released.

Dermatology and plastic surgery practices go through the same NPI verification step regardless of practice size.

What to request before adding a biologics line

Aesthetic practices evaluating a new supplier should request the certificate of analysis and donor eligibility summary for the specific lot under consideration, along with a description of how the supplier reports processing and release testing. For exosome products specifically, ask for the supplier's characterization data rather than relying on marketing claims about particle counts alone.

Full ingredient disclosures for lyophilized exosome products are provided to verified accounts on request.

Receiving shipments at a medspa or dermatology office

Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers and require prompt receiving on the scheduled delivery day; lyophilized exosome formats are shelf-stable and do not require refrigerated storage under normal conditions. A Rochester practice should plan front-desk coverage around whichever format it has ordered rather than assuming every shipment needs the same handling.

Verifying regulatory posture with counsel

Before marketing or offering any product, a practice's medical director and counsel should review how its intended use is classified and confirm current requirements with the New York medical board. Precision Biologics can supply documentation to support that review, including registration and licensure records on request, but the classification decision itself is the practice's responsibility.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.